Author

Jinshan Shen

Observed institutions: University of Iowa, Bristol-Myers Squibb (United States), Radius Health (United States), Gossamer Bio (United States), Relay Therapeutics (United States)

ORCID: 0000-0003-1428-9098

Observed ORCID: 0000-0003-1428-9098

OpenAlex ID: A5102406332

Five-Year Safety and Efficacy of Belatacept in Renal Transplantation

2010 · Flavio Vincenti, Gilles Blancho, et al. · Journal of the American Society of Nephrology · 189

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients

2013 · Jinshan Shen, Robert Townsend, et al. · Clinical Drug Investigation · 43

Pharmacokinetic and Drug–Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor

2019 · Varun Garg, Jinshan Shen, et al. · Clinical and Translational Science · 35

A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild‐to‐moderate asthma

2019 · Hector Ortega, Mary Fitzgerald, et al. · Clinical & Experimental Allergy · 16

First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors.

2021 · Alison M. Schram, Suneel Deepak Kamath, et al. · Journal of Clinical Oncology · 13

Abstract P02-02: First results of RLY-4008, a potent and highly selective FGFR2 inhibitor in a first-in-human study in patients with FGFR2-altered cholangiocarcinoma and multiple solid tumors

2021 · Lipika Goyal, Mitesh Borad, et al. · Molecular Cancer Therapeutics · 12

Evaluation of RAD1901, a novel investigational, selective estrogen receptor degrader (SERD), for the treatment of ER-positive (ER+) advanced breast cancer.

2017 · Aditya Bardia, Peter Kabos, et al. · Journal of Clinical Oncology · 12

Immunohistochemical demonstration of β-naphthoflavone-inducible cytochrome P450 1A1/1A2 in rat intrahepatic biliary epithelial cells

1998 · Jinshan Shen, Jadine A. Moy, et al. · Hepatology · 11

First-in-human global multi-center study of RLY-2608, a pan-mutant and isoform-selective PI3Kα inhibitor, as a single agent in patients with advanced solid tumors and in combination with fulvestrant in patients with advanced breast cancer.

2022 · Cesar Augusto Perez, Jason Timothy Henry, et al. · Journal of Clinical Oncology · 5

First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain–Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors

2024 · Melissa L. Johnson, Beni B. Wolf, et al. · Molecular Cancer Therapeutics · 3

Abstract PS7-01: Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial

2025 · Cristina Saura, Sarah L. Sammons, et al. · Clinical Cancer Research · 2

P066 Gb004, a Novel Gut-targeted Prolyl Hydroxylase Inhibitor for Inflammatory Bowel Disease: First-in-human, Mutliple-dose Study in Healthy Subjects With Gut Biopsies

2020 · Barrett Levesque, Kristen Taylor Meadows, et al. · Gastroenterology · 2

Supplementary Data from First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain–Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors

2025 · Melissa L. Johnson, Beni B. Wolf, et al.

Data from First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain–Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors

2025 · Melissa L. Johnson, Beni B. Wolf, et al.

Tu1882 GB004, A NOVEL PROLYL HYDROXYLASE INHIBITOR FOR INFLAMMATOYR BOWEL DISEASE, LEADS TO GUT-TARGETED HIF-1ALPHA PATHWAY ENGAGEMENT IN A MULTIPLE DOSE STUDY IN HEATHY SUBJECTS

2020 · Barrett G. Levesque, Kristen Taylor Meadows, et al. · Gastroenterology

Works count: 15

Citation count: 343

H-index: 8

I10-index: 8